Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 13.06
- Piotroski Score 0.00
- Grade Sell
- Symbol (VRTX)
- Company Vertex Pharmaceuticals Incorporated
- Price $516.74
- Changes Percentage (2.84%)
- Change $14.29
- Day Low $504.94
- Day High $519.88
- Year High $519.88
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF 6 years of age or older who have at least one F508del mutation. Its pipeline includes VX-864 for the treatment of AAT deficiency, which is in Phase 2 clinical trial; VX-147 for the treatment of APOL1-mediated focal segmental glomerulosclerosis, or FSGS, and other serious kidney diseases which is in Phase 2 clinical trial; VX- 880, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-548, a NaV1.8 inhibitor for treatments of acute, neuropathic, musculoskeletal pain which is in Phase 2 clinical trial; and CTX001 for the treatment severe SCD and TDT which is in Phase 3 clinical trial. The company sells its products primarily to specialty pharmacy and specialty distributors in the United States, as well as specialty distributors and retail chains, and hospitals and clinics internationally. It has collaborations with Affinia Therapeutics, Inc.; Arbor Biotechnologies, Inc.; CRISPR Therapeutics AG.; Kymera Therapeutics, Inc.; Mammoth Biosciences, Inc.; Moderna, Inc.; Obsidian Therapeutics, Inc.; and Skyhawk Therapeutics, Inc.; as well as Ribometrix, Inc.; Genomics plc; Merck KGaA; Darmstadt, Germany, and X-Chem, Inc. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 02/02/2025
- Fiscal Year End N/A
- Average Stock Price Target $365.00
- High Stock Price Target $600.00
- Low Stock Price Target $240.00
- Potential Upside/Downside N/A
- Consensus Rating Buy
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) $15.39
- Trailing P/E Ratio 31.39
- Forward P/E Ratio 31.39
- P/E Growth 31.39
- Net Income $3.62 B
Income Statement
Quarterly
Annual
Latest News of VRTX
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Vertex Pharmaceuticals (VRTX) Q3 2024 Earnings Call Transcript
Vertex Pharmaceuticals recently held a call discussing their Q3 results and future plans. They highlighted strong performance in their CF and CASGEVY launches, with potential approvals in early 2025....
By Yahoo! Finance | 3 days ago -
Vertex Pharmaceuticals Incorporated (VRTX): Why Do Hedge Funds Recommend This Biotech Stock?
A review of the 12 Best Biotech Stocks by hedge funds includes a spotlight on Vertex Pharmaceuticals (NASDAQ:VRTX). The biotech industry is projected to grow significantly, with Vertex being a top con...
By Yahoo! Finance | 2 months ago -
Vertex Pharmaceutical Inc. (VRTX): Jim Cramer's Go-To Stock For Success
The article discusses Jim Cramer's views on Nvidia's market behavior and the broader implications for investors. Despite strong financial performance, the stock fell due to high expectations. Cramer s...
By Yahoo! Finance | 2 months ago
